The stock of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has decreased by -3.66 when compared to last closing price of 13.66.Despite this, the company has seen a loss of -17.90% in its stock price over the last five trading days. benzinga.com reported 2024-11-19 that On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
The stock has a 36-month beta value of 1.04. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RCKT is 83.00M, and at present, short sellers hold a 14.33% of that float. On November 20, 2024, the average trading volume of RCKT was 861.52K shares.
RCKT’s Market Performance
The stock of Rocket Pharmaceuticals Inc (RCKT) has seen a -17.90% decrease in the past week, with a -25.31% drop in the past month, and a -34.20% fall in the past quarter. The volatility ratio for the week is 7.25%, and the volatility levels for the past 30 days are at 5.27% for RCKT. The simple moving average for the past 20 days is -19.70% for RCKT’s stock, with a -40.33% simple moving average for the past 200 days.
Analysts’ Opinion of RCKT
Goldman, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $39. The rating they have provided for RCKT stocks is “Neutral” according to the report published on April 02nd, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to RCKT, setting the target price at $65 in the report published on October 24th of the previous year.
RCKT Trading at -24.79% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.54% of loss for the given period.
Volatility was left at 5.27%, however, over the last 30 days, the volatility rate increased by 7.25%, as shares sank -25.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.82% lower at present.
During the last 5 trading sessions, RCKT fell by -17.90%, which changed the moving average for the period of 200-days by -54.05% in comparison to the 20-day moving average, which settled at $16.39. In addition, Rocket Pharmaceuticals Inc saw -56.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from White Mark Andrew, who sale 3,080 shares at the price of $16.62 back on Oct 31 ’24. After this action, White Mark Andrew now owns 69,140 shares of Rocket Pharmaceuticals Inc, valued at $51,205 using the latest closing price.
Militello John, the of Rocket Pharmaceuticals Inc, sale 917 shares at $16.62 during a trade that took place back on Oct 31 ’24, which means that Militello John is holding 50,534 shares at $15,245 based on the most recent closing price.
Stock Fundamentals for RCKT
Current profitability levels for the company are sitting at:
- -26.55 for the present operating margin
- 0.05 for the gross margin
The net margin for Rocket Pharmaceuticals Inc stands at -25.03. The total capital return value is set at -0.77. Equity return is now at value -59.27, with -52.01 for asset returns.
Currently, EBITDA for the company is -236.62 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 112.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.05.
Conclusion
To sum up, Rocket Pharmaceuticals Inc (RCKT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
